Dermatitis : contact, atopic, occupational, drug最新文献

{"title":"Results of Photopatch Testing in Israel: A Retrospective Cohort Study.","authors":"Daniel Hilewitz, Akiva Trattner, Stav Endelman, Michal Solomon, Guy Zvi Katzir Kutzinogi, Assi Levi, Shiri Daniel Mimouni, Igor Snast","doi":"10.1177/17103568251378517","DOIUrl":"https://doi.org/10.1177/17103568251378517","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> There are limited data regarding photopatch testing (PPT) in Israel. <u><b><i>Objectives:</i></b></u> To investigate the prevalence of positive reactions and concurrent diagnosis of patients that underwent PPT in a single center in Israel. <u><b><i>Methods:</i></b></u> Retrospective cohort study that included all patients that were suspected of having contact dermatitis and underwent patch testing with the European baseline series (EBS) and additionally were selectively PPT with the Scandinavian/European baseline photopatch series in a tertiary medical center in Israel (2009-2023). <u><b><i>Results:</i></b></u> Of 5234 consecutive patients tested with the EBS, 78 (1.5%) underwent PPT. Overall, 23 (29.49%) patients demonstrated positive PPT results, and 13 (56.52%; 17 positive reactions, 12 different allergens) exhibited clinically relevant reaction and were diagnosed with photoallergic contact dermatitis (PACD). Sunscreen-related allergens represented the most common relevant photoallergens (6 patients, 46.15%), with benzophenone-3 yielding positive and relevant results in 5 cases. The duration of symptoms was significantly (<i>P</i> < 0.05) longer among 13 patients with relevant PPT reaction that were diagnosed with PACD (12.16 ± 12.44 years) compared with patients with irrelevant (4.86 ± 6.75 years) or negative results (5.29 ± 7.98 years). The most common final diagnosis was allergic contact dermatitis (ACD) (21 cases, 26.92%), followed by PACD (13 cases, 16.66%), nonspecific dermatitis (5 cases, 6.41%), or atopic dermatitis (4 cases, 5.13%). About half (48.71%) of patients had indeterminate or other diagnoses, including rosacea, solar urticaria, polymorphic light eruption, and collagen vascular disease. <u><b><i>Conclusion:</i></b></u> In this retrospective Israeli study, the prevalence of positive PPT was relatively high (29%); however, falls within the wide range of reported values. Sunscreen-related allergens, specifically benzophenone-3, were the most common culprit. Among PACD patients, time-to-diagnosis was significantly delayed compared to other patients. Although the final diagnosis was heterogenous, ACD was the most common type.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145034902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Artificial Intelligence in Contact Dermatitis: Current and Future Perspectives.","authors":"Akriti Agrawal","doi":"10.1177/17103568251376647","DOIUrl":"https://doi.org/10.1177/17103568251376647","url":null,"abstract":"<p><p><u><b><i></i></b></u> Contact dermatitis (CD), which includes both allergic CD and irritant CD, is a common inflammatory condition that can pose significant diagnostic challenges. Although patch testing is the gold standard for identifying causative allergens for allergic contact dermatitis (ACD), it is time-consuming, subjective, and requires expert interpretation. Recent advancements in artificial intelligence (AI), particularly in machine learning (ML) and deep learning, have shown promise in improving the accuracy, efficiency, and accessibility of CD diagnosis and management. This review explores current applications of AI in CD, drawing from 12 original studies that investigated AI-based image analysis, biomarker discovery, and patient risk profiling. Convolutional neural networks demonstrated high diagnostic accuracy (up to 99.5%) in interpreting patch test images, while ML algorithms successfully identified transcriptomic signatures distinguishing allergic CD from irritant CD. In addition, AI has been used to predict positive patch test outcomes and identify high-risk patients based on clinical and occupational factors. Despite these promising developments, limitations such as dataset bias, lack of standardization, and model interpretability remain. Nevertheless, AI represents a transformative tool in dermatology, offering the potential for standardized diagnostics, personalized care, and enhanced accessibility.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145014909","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>Letter:</i> Reduced Risk of Neurodevelopmental and Psychiatric Disorders With Dupilumab Use in Pediatric Atopic Dermatitis.","authors":"Amritpal Kooner, Abhinav Janappareddi, Leo Wan, Sheehan Parvez, Peter Lio","doi":"10.1177/17103568251376644","DOIUrl":"10.1177/17103568251376644","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983738","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acrylates Induced Oral Lichenoid Lesions with Generalized Lichen Planus Pigmentosus.","authors":"Ines Lahouel, Mounira Ben Yahia, Houda Abdelwahed, Hichem Belhadjali, Monia Youssef, Jameleddine Zili","doi":"10.1177/17103568251376639","DOIUrl":"10.1177/17103568251376639","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144983813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Updates to the Research Institute for Fragrance Materials, Inc. Confirmation of No Induction in Human Test Standard Protocol.","authors":"Maura Lavelle, Isabelle Lee, Devin O'Brien, Mihwa Na, Anne Marie Api","doi":"10.1089/derm.2025.0125","DOIUrl":"10.1089/derm.2025.0125","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> At the recommendation of the Expert Panel for Fragrance Safety, the Research Institute for Fragrance Materials, Inc. (RIFM) considered adopting a 48-hour challenge for confirmation of no induction in human (CNIH) studies in order to more closely mimic the patch testing conducted by dermatologists assessing allergic contact dermatitis. <u><b><i>Objectives:</i></b></u> A pilot study was undertaken to ensure that adopting a new protocol would not invalidate the 30+ years of human patch-testing data collected by RIFM. <u><b><i>Methods:</i></b></u> Two protocols were simultaneously tested to determine if a 48-hour challenge patching would result in reactions significantly different from those produced during a 24-hour challenge patching. RIFM tested 19 fragrance materials, including key ingredients in natural complex substances. <u><b><i>Conclusions:</i></b></u> Although patching for 48 hours is more sensitive than patching for 24 hours, during this pilot, no significant differences in sensitization were noted between the two challenge protocols when 2317 subjects were tested with 19 test materials, a vehicle control, and a saline control. Therefore, adopting this new 48-hour challenge patching for RIFM-conducted CNIHs does not invalidate previously published studies conducted according to the 2008 RIFM standard protocol, which utilized a 24-hour patching during the challenge phase.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"516-521"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144289774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upadacitinib in Moderate-to-Severe Atopic Dermatitis: Real-Life Study of Long-Term Efficacy, Safety and Correlation Between Clinical Effectiveness and Subjective Perception of Disease.","authors":"M Bertello, E Cinotti, P Rubegni, L Mastorino, G Passaro, M Ortoncelli, P Quaglino, S Ribero","doi":"10.1089/derm.2024.0346","DOIUrl":"10.1089/derm.2024.0346","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"545-548"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142396238","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identification of Early and Late Responders to Anti-IL-13 Antibody Tralokinumab in Atopic Dermatitis: A Real-World Japanese Study.","authors":"Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, Naoko Kanda","doi":"10.1089/derm.2024.0460","DOIUrl":"10.1089/derm.2024.0460","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> Tralokinumab, an anti-IL-13 antibody, is an effective treatment for patients with atopic dermatitis (AD). However, predictive factors for responders to tralokinumab remain unclear in real-world practice. <u><b><i>Objective:</i></b></u> This study aimed to identify predictive factors for early and late responders to tralokinumab treatment. Early responders were defined as patients achieving investigator's global assessment (IGA) 0/1 at week 12, whereas late responders were defined as those without IGA 0/1 at week 12 but achieving IGA 0/1 at week 24. <u><b><i>Methods:</i></b></u> A prospective study was conducted with 108 Japanese AD patients treated with tralokinumab between October 2023 and August 2024. Patients' background factors and baseline clinical or laboratory indexes were compared between responders and poor responders. <u><b><i>Results:</i></b></u> Both early and late responders had a higher proportion of systemic therapy-naive patients compared with poor responders. Early responders had higher proportion of females, younger age, shorter disease duration, lower body mass index, and monocyte-to-lymphocyte ratio, whereas late responders had lower immunoglobulin E, thymus and activation-regulated chemokine, platelet-to-lymphocyte ratio, and C-reactive protein compared with poor responders. <u><b><i>Conclusions:</i></b></u> This study provides valuable insights for optimizing treatment strategies in AD, in selecting patients who may respond to tralokinumab at early or late phases.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"500-508"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142901315","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Filaggrin Gene Variants Among Patients With Atopic Dermatitis in Turkey: A Multicenter Study Investigating Its Relationship With Disease Severity and Clinical/Laboratory Findings.","authors":"Yasemin Erdem, Esen Özkaya, Yücel Erbilgin, Merve Saritas, Müge Sayitoglu, Özlem Su Küçük, Andaç Salman, Ayse Deniz Yucelten, Emek Kocatürk, Oktay Taskapan, Ahmet Gul","doi":"10.1089/derm.2024.0403","DOIUrl":"10.1089/derm.2024.0403","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"550-553"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142960456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Para-Phenylenediamine-Induced Lichenoid Eruption With Involvement of the Oral Mucosa and Subsequent Contact Leukoderma.","authors":"Karama Sboui, Ines Lahouel, Hichem Belhadjali, Yosra Soua, Monia Youssef, Jameleddine Zili","doi":"10.1089/derm.2024.0249","DOIUrl":"10.1089/derm.2024.0249","url":null,"abstract":"","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"522-523"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143049147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"North American Contact Dermatitis Group Patch Test Results: 2021-2022.","authors":"Marie-Claude Houle, Joel G DeKoven, Amber Reck Atwater, Margo J Reeder, Erin M Warshaw, Melanie D Pratt, Donald V Belsito, Brandon L Adler, Jonathan Silverberg, JiaDe Yu, Nina Botto, Christen M Mowad, Cory A Dunnick, James S Taylor","doi":"10.1089/derm.2024.0474","DOIUrl":"10.1089/derm.2024.0474","url":null,"abstract":"<p><p><u><b><i></i></b></u> <u><b><i>Background:</i></b></u> Patch testing is an important diagnostic tool for the assessment of allergic contact dermatitis (ACD). <u><b><i>Objective:</i></b></u> This study documents the North American Contact Dermatitis Group (NACDG) patch testing results from 2021 to 2022. <u><b><i>Methods:</i></b></u> At 12 centers in North America, patients were tested in a standardized manner with a screening series of 80 allergens. <u><b><i>Results:</i></b></u> Overall, 3056 patients were tested; 2200 (72.0%) had at least 1 positive/allergic patch test reaction and 1412 patients (46.6%) had a primary diagnosis of ACD. The most commonly positive allergens were nickel sulfate hexahydrate 5% and 2.5% petrolatum (24.9% and 22.1%, respectively), methylisothiazolinone (MI) (11.5%), hydroperoxides of linalool (10.1%), cobalt chloride hexahydrate (9.2%), and methylchloroisothiazolinone/methylisothiazolinone (9.0%). Compared with 2019-2020, prevalence of the top 20 allergens statistically increased for nickel (<i>P</i> < 0.001), cobalt (<i>P</i> < 0.01), gold (<i>P</i> < 0.001), hydroperoxides of limonene (<i>P</i> < 0.001), oleamidopropyl dimethylamine (<i>P</i> < 0.01), dimethylaminopropylamine (<i>P</i> < 0.01), and ammonium persulfate (<i>P</i> < 0.001). MI positivity continued to decrease from its peak in 2017-2018. More than one-fifth of patients (n = 640, 21.1%) had at least one clinically relevant reaction to an allergen/substance not present in the NACDG screening series. <u><b><i>Conclusions:</i></b></u> The epidemic of MI contact allergy in North America appears to continue its descent. Fragrance allergy is still very common, but the composition of fragrance allergy markers appears to be changing. Patch testing using a robust screening series, and supplemental allergens as indicated, is necessary for the comprehensive evaluation of ACD.</p>","PeriodicalId":93974,"journal":{"name":"Dermatitis : contact, atopic, occupational, drug","volume":" ","pages":"464-476"},"PeriodicalIF":3.2,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144052216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}